Inflammatory bowel disease: clinical aspects and established and evolving therapies

@article{Baumgart2007InflammatoryBD,
  title={Inflammatory bowel disease: clinical aspects and established and evolving therapies},
  author={Daniel C. Baumgart and William J. Sandborn},
  journal={The Lancet},
  year={2007},
  volume={369},
  pages={1641-1657}
}

Figures and Tables from this paper

Small Molecule Drugs in Inflammatory Bowel Diseases

An updated and complete review of the most recently authorized SMDs and SMDs in phase II/III development for Crohn’s disease and Ulcerative Colitis.

What We Can Learn from Current Inflammatory Bowel Disease (IBD) Biological Therapy—Dose Regimen and Others

Lessons learned from current IBD biological therapy may help enhance the clinical development efficiency of future biologics, e.g., test a wide dose range; characterize full dose-response for desirable and untoward effects; understand influencing factors to the treatment (and placebo) effect; and leverage dose-ranging learning between CD and UC.

Biological therapies for inflammatory bowel diseases.

Infliximab, a chimeric immunoglobulin (Ig)G1 monoclonal antibody to tumor necrosis factor, dramatically improved treatment of patients with Crohn's disease and ulcerative colitis and has achieved treatment goals such as mucosal healing and decreasing the need for hospitalizations and surgeries.

Novel therapeutic targets for inflammatory bowel disease.

[Emerging drugs in the treatment of inflammatory bowel disease: beyond anti-TNF-α].

  • Kyeong Ok KimB. Jang
  • Biology, Medicine
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • 2011
The present paper reviews the action mechanism, short or long term efficacy and safety of variable drugs other than anti-TNF-a in IBD and describes the five novel anti-cytokines developed.

Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?

The immunology of the gut and the mechanism of action these emerging therapies for IBD are reviewed and the positioning of therapies and potential alterations to therapeutic algorithms as new medications emerge are discussed.

Biologics, novel therapeutic alternatives in inflammatory bowel disease

Evidence supports the theory that biologics not only control symptoms of CD but also may potentially alter the natural course of disease, however, economic costs and the risks of severe opportunistic infections associated with biologic therapy have still not settled the appropriate role for these agents in the clinical care of patients with IBD.

Gut inflammation: current update on pathophysiology, molecular mechanism and pharmacological treatment modalities.

Based on extensive research over the last decade, besides the conventional therapy, there are several novel pathways and specific targets, on which focus new therapeutics that aim to correct genetic susceptibility or restore the immune dysregulation.

Drug-Induced Inflammatory Bowel Disease and IBD-Like Conditions

A comprehensive literature review was performed on drugs implicated in the development of new onset IBD to clarify the confusion and suggest different pathogenic mechanisms for different drugs listed above.

Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update

The goal of this review is to provide an update and analyze the pros and cons of using anti-TNF therapies in the treatment of IBD.
...

References

SHOWING 1-10 OF 175 REFERENCES

Review article: systemic and topical steroids in inflammatory bowel disease.

There is no place for long-term steroid treatment in ulcerative colitis and very little in Crohn's disease--immunosuppression with azathioprine or related drugs is certainly the better alternative.

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease

Subcutaneous rhuIL-10 administered daily for 28 days to patients with mild to moderately active Crohn's disease is safe, well-tolerated, and shows clinical and endoscopic improvement.

Systemic and topical steroids in inflammatory bowel disease

There is no place for long‐term steroid treatment in ulcerative colitis and very little in Crohn's disease — immunosuppression with azathioprine or related drugs is certainly the better alternative.

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.

Subcutaneous treatment with rhuIL-10 induced a fully reversible, dose-dependent decrease in hemoglobin and thrombocyte counts but no clinically significant side effects and a tendency toward clinical improvement but not remission was observed in the 8-microg/kg dose group.

Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

  • S. SchreiberB. Feagan J. Steffgen
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2006

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease

Subcutaneous treatment with rhuIL-10 over 28 days induced a fully reversible, dose-dependent decrease in hemoglobin and thrombocyte counts but no clinically significant side effects and up to 8 μg/kg of rhu IL-10 was well tolerated.

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

Patients with moderate ulcerative colitis who are treated with daclizumab are not more likely to be in remission or response at eight weeks than patients treated with placebo.

Infliximab for induction and maintenance therapy for ulcerative colitis.

Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.

Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease

Treating active CD with fontolizumab was well tolerated and resulted in increased rates of clinical response and remission compared with placebo, and Stratification according to elevated baseline C reactive protein levels resulted in a decreased placebo response and pronounced differences in clinical benefit.
...